Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

June 30, 2018

Study Completion Date

June 30, 2018

Conditions
Purpura, Thrombocytopenic, IdiopathicAutoimmune Thrombocytopenic PurpuraAutoimmune ThrombocytopeniaChronic Lymphocytic LeukemiaNon Hodgkin's Lymphoma
Interventions
DRUG

Eltrombopag Olamine

"Initial dose : 50 mg/day for 14 days.~Next doses:~1. If platelet count \<60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).~2. If platelet count \>60000/µL and ≤200000/µL same dose for the next 14 days.~3. If platelet count \>200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.~4. If platelet count \>400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is \<150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."

Trial Locations (1)

36100

Department of Hematology, Ospedale San Bortolo, Vicenza

All Listed Sponsors
lead

Fondazione Progetto Ematologia

OTHER

NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | Biotech Hunter | Biotech Hunter